Clinical Trial Update: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atezolizumab plus one-year BCG instillations in BCG-naive high-risk non-muscle invasive bladder cancer patients; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bacillus Calmette-Guérin (intravesical instillation) (Bacillus Calmette-Guérin)

Snippet

Sponsor: UNICANCER | Conditions: Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING